News & Updates

Actively treating even mild hypertension to a target blood pressure (BP) of <140/90 mm Hg in pregnant women significantly lowers the risk of adverse pregnancy outcomes without apparent harm to the foetus compared with a strategy of reserving treatment to only when hypertension becomes severe (≥160/105 mm Hg), according to the CHAP* study presented at ACC 2022.

Use of the dopamine 3 receptor agonist pramipexole (PPX) as adjuvant therapy appears to facilitate the reduction of patient exposure to opioids and its associated risks, according to a study.

The use of mitapivat increased haemoglobin (Hb) levels in patients with pyruvate kinase deficiency (PKD) who did not receive any regular blood transfusions, according to the ACTIVATE* study.

Taking P2B001, a novel polypill comprising fixed-dose combination of 0.6 mg pramipexole (PPX) and 0.75 mg of rasagiline (RAS), was better than taking either drug component alone for symptomatic control of Parkinson’s disease, according to results of a late-breaking phase III study presented at AAN 2022.

Using the antifibrinolytic tranexamic acid (TXA) during noncardiac surgery significantly reduces bleeding without significant increases in vascular complications in patients at risk for these complications, according to the POISE-3* trial presented at ACC 2022.